79 related articles for article (PubMed ID: 10396332)
1. [Assay and detection methods for urokinase-type plasminogen activator and its related-factors].
Kimura K; Endo Y; Sasaki T
Gan To Kagaku Ryoho; 1999 Jun; 26(7):1009-17. PubMed ID: 10396332
[TBL] [Abstract][Full Text] [Related]
2. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
3. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.
Declerck PJ; Van Keer L; Verstreken M; Collen D
Thromb Haemost; 1992 Jan; 67(1):95-100. PubMed ID: 1377417
[TBL] [Abstract][Full Text] [Related]
4. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
[TBL] [Abstract][Full Text] [Related]
6. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
[TBL] [Abstract][Full Text] [Related]
7. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
Darras V; Thienpont M; Stump DC; Collen D
Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
[TBL] [Abstract][Full Text] [Related]
8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
9. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
10. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
[TBL] [Abstract][Full Text] [Related]
11. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
12. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B
Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314
[TBL] [Abstract][Full Text] [Related]
14. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
15. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
Muth H; Maus U; Wygrecka M; Lohmeyer J; Grimminger F; Seeger W; Günther A
Crit Care Med; 2004 Jan; 32(1):217-26. PubMed ID: 14707582
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
Li H; Dong S; Zeng Y
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
[TBL] [Abstract][Full Text] [Related]
17. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
[TBL] [Abstract][Full Text] [Related]
18. Differential detection of single-chain and two-chain urokinase-type plasminogen activator by a new immunoadsorbent-amidolytic assay (IAA).
Corti A; Nolli ML; Cassani G
Thromb Haemost; 1986 Dec; 56(3):407-10. PubMed ID: 3105110
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen.
Li C; Gurewich V; Liu JN
Exp Cell Res; 1996 Aug; 226(2):239-42. PubMed ID: 8806427
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Ohta S; Fuse H; Fujiuchi Y; Nagakawa O; Furuya Y
Anticancer Res; 2003; 23(3C):2945-50. PubMed ID: 12926141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
